07:00 , Apr 30, 2012 |  BioCentury  |  Emerging Company Profile

Ariel: Antagonizing pain

Although standard of care treatments raise safety concerns, along with high rates of non-responders, the pipeline for acute pain continues to be short on novel targets. Ariel Pharmaceuticals Inc. is developing an in-licensed PTGER4 antagonist...
07:00 , Sep 26, 2011 |  BC Week In Review  |  Company News

Ariel Pharmaceuticals, BTG deal

BTG granted Ariel exclusive, worldwide rights to develop and commercialize prostaglandin E2 (PGE2) receptor EP4 subtype ( Prostanoid EP4 receptor ; PTGER4 ) antagonist AP-1531 . Ariel plans to start a Phase II trial for...